Kronos Bio(US:KRON) Newsfilter·2024-05-23 21:15Core Insights - Kronos Bio, Inc. announced new data from its ongoing Phase 1/2 study of KB-0742, demonstrating a manageable safety profile with no grade 3/4 neutropenia observed [1][6] - The study focuses on patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma, with promising results leading to confidence in the efficacy of the 80mg dose schedule [2][3] Study Details - The ongoing study, KB-0742-1001, is a first-in-human, open-label dose escalation and cohort expansion trial [1][9] - Preliminary efficacy data presented at the 2023 AACR-NCI-EORTC meeting showed anti-tumor activity in transcriptionally addicted tumors, including a partial response at the 60mg dose [4] Dosage and Efficacy - The 80mg four-days-on, three-days-off dosing schedule is currently enrolling patients, with expectations for increased efficacy compared to the 60mg schedule [5][6] - Pharmacokinetic modeling indicates that the 80mg schedule results in over a ten-fold increase in time above a preclinically determined efficacy threshold compared to the 60mg schedule [6] Patient Data - Data from 103 patients treated with KB-0742 at 60mg (n=82) and 80mg (n=21) showed manageable adverse events, with nausea (69.9%) and vomiting (52.4%) being the most common [6] - Patients remained on treatment for an average of over 2 cycles, with a maximum of 14 completed cycles, and less than 10% discontinued due to adverse events [6] Future Plans - The expansion cohort at the 80mg dose is expected to begin enrollment in the third quarter of 2024 [3][5] - The company is optimistic about the potential benefits of the 80mg dosing schedule based on the data presented [2][3]